Elucidation of factors enhancing the expression of CD20 and thereby efficiency of CD20 monoclonal antibodies through epigenetic drug screening of resistant CLL cells

Warning

This publication doesn't include Faculty of Medicine. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	KOZLOVÁ Veronika LEDEREROVÁ Aneta MANČÍKOVÁ Veronika MAYER Jiří POSPÍŠILOVÁ Šárka DOUBEK Michael ŠMÍDA Michal
Year of publication	2020
Type	Conference abstract
MU Faculty or unit	Central European Institute of Technology
Citation
Description	In spite of recent advancements in the therapy of B-cell malignancies, CD20-targeted monoclonal antibodies (mAbs) still remain the key part of therapy in clinical practice. Furthermore, the combination of CD20 mAbs with targeted agents is being tested in clinical trials. Therefore, the knowledge of CD20 regulation remains a critical issue to address. Despite using CD20 as the prime target of therapy for decades now, the information about its function and molecular mechanisms remains to be scarce. Since low expression of CD20 on the surface of malignant B cells represents an important basis for CD20 antibody therapy failure, the idea of modulating CD20 levels seems an appealing strategy to enhance the success rate of CD20 immunotherapy
Related projects:	Rezistence na léčbu monoklonálními protilátkami u B-CLL a B-lymfomů: příčiny vzniku a potenciální intervenční strategie CEITEC 2020 Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI